NCT05063110View on ClinicalTrials.gov

Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB

PHASE2UnknownINTERVENTIONAL

Enrollment

63

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

November 1, 2023

Study Completion Date

February 1, 2024

Conditions

Adults Patients Having Non Severe HLH

Interventions

DRUG

Itacitinib

Administration of 300 mg of ITACITINIB per os every day for 30 days.

Trial Locations (1)

93000

RECRUITING

Hôpital Avicenne, Bobigny

Sponsors

Collaborators (1)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER